<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00202371</url>
  </required_header>
  <id_info>
    <org_study_id>01-021</org_study_id>
    <nct_id>NCT00202371</nct_id>
  </id_info>
  <brief_title>Transfusion Effects in Myelodysplastic Patients: Limiting Exposure</brief_title>
  <official_title>Transfusion Effects in Myelodysplastic Patients: Limiting Exposure (Temple)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanquin Research &amp; Blood Bank Divisions</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Netherlands: Ministry of Health, Welfare and Sports</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanquin Research &amp; Blood Bank Divisions</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study was to compare a restrictive RBC transfusion policy (a Hb transfusion
      trigger: 7.2 gr/dl) with a more liberal RBC transfusion policy (a Hb transfusion trigger: 9.6
      gr/dl) on physical fatigue.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this study was to compare a restrictive RBC transfusion policy (a Hb transfusion
      trigger of 7.2 gr/dl) with a more liberal RBC transfusion policy (a Hb transfusion trigger of
      9.6 gr/dl) on physical fatigue.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Too few inclusions
  </why_stopped>
  <start_date>July 2002</start_date>
  <completion_date type="Anticipated">July 2005</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>fatigue</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Health related Quality of Life, Blood usage and the costs, Haemoglobin increase after transfusion, Heart beat, blood pressure, temperature, platelet count, Development of RBC alloantibodies, Mortality</measure>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Red Blood Cell transfusion</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis myelodysplastic syndrome (primary or secondary) based on cytopenia in at
             least 1 cell line + dysplasia in 2 cell lines (and no other cause (especially
             deficiencies)) and a pathologic anatomic diagnosis after bone marrow punction.

          -  refractory anaemia (RA): blood: ≤ 1% blasts, ≤ 1 x 109 monocytes; bone marrow: &lt; 5%
             blasts, ringed sideroblasts ≤ 15% of the erythroid cells

          -  refractory anaemia with ringed sideroblasts (RARS): blood: ≤ 1% blasts, ≤ 1 x 109
             monocytes; bone marrow: &lt; 5% blasts, ringed sideroblasts &gt; 15% of the erythroid cells

          -  refractory anaemia with excess blasts (RAEB): blood: &lt; 5% blasts, ≤ 1 x 109 monocytes;
             bone marrow: blasts ≥ 5 -≤ 20%

          -  chronic myelomonocytic leukaemia (CMML): blood: &gt;1 x 109/l monocytes, &lt;5% blasts; bone
             marrow: blasts &lt; 20%, increase of the monocytic component

          -  erythrocyte transfusion need

          -  working knowledge of the national language

          -  written consent for participating this study (informed consent)

        Exclusion Criteria:

          -  candidate for bone marrow- or organ transplantation

          -  medication: growth factors (GM-CSF), or EPO

          -  patients who will receive an intensive chemotherapeutic treatment with a cytopenia,
             expected longer than 2 weeks

          -  refractory anaemia with excess blasts in transformation (RAEB-t): blood: ≥ 5% blasts
             or Auer rods; bone marrow: or blasts &gt; 20 - &lt; 30% or Auer rods

          -  pregnancy at the moment of inclusion

          -  patients with congenital severe haemolytic anaemia, like thalassemia or sickle cell
             anaemia

          -  patients with AIDS or a severe congenital or acquired (e.g. iatrogenic) immunological
             disorder

          -  severe active infections at the moment of inclusion

          -  severe cardiac, pulmonal, neurological, metabolic or psychiatric disease at the moment
             of inclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dick J van Rhenen, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Sanquin Blood Bank South West Region</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanquin Blood Bank South West Region</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>June 1, 2015</last_update_submitted>
  <last_update_submitted_qc>June 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 2, 2015</last_update_posted>
  <keyword>MDS, Fatigue, RBC transfusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

